Welcome to LookChem.com Sign In|Join Free
  • or
2,2'-Dibromodiethyl ether, also known as Bis(2-bromoethyl) ether, is a halogen-containing ether compound with two terminal bromine atoms. It is a colorless liquid that has been prepared by reacting dioxane with anhydrous, bromine-free hydrogen bromide. 2,2'-Dibromodiethyl ether serves as an important organic intermediate for the synthesis of various substituted diethyl ether products and can be utilized as a building block for a variety of pharmaceutical compounds and materials.

5414-19-7

Post Buying Request

5414-19-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5414-19-7 Usage

Uses

Used in Organic Synthesis:
2,2'-Dibromodiethyl ether is used as an important organic intermediate for the synthesis of substituted diethyl ether products. Its unique structure with terminal bromine atoms allows for further chemical reactions and modifications, making it a valuable building block in the creation of a wide range of compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,2'-Dibromodiethyl ether is used as a building block for the development of various pharmaceutical compounds and materials. Its versatility in chemical reactions and compatibility with other molecules make it a promising candidate for the creation of new drugs and therapeutic agents.
Used in Specific Chemical Preparations:
2,2'-Dibromodiethyl ether may be used in the preparation of 1,4,7-trioxa-10-19-dithia-13,16-diaza-12,17-dioxo-8,9,14,15,20,21-tribenzoheneicosane, a complex organic compound with potential applications in various fields. The use of 2,2'-Dibromodiethyl ether in this preparation highlights its importance as a versatile building block in the synthesis of complex molecules.

Check Digit Verification of cas no

The CAS Registry Mumber 5414-19-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,1 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 5414-19:
(6*5)+(5*4)+(4*1)+(3*4)+(2*1)+(1*9)=77
77 % 10 = 7
So 5414-19-7 is a valid CAS Registry Number.
InChI:InChI=1/C4H8Br2O/c5-1-3-7-4-2-6/h1-4H2

5414-19-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (L11510)  Bis(2-bromoethyl) ether, 96%   

  • 5414-19-7

  • 5g

  • 268.0CNY

  • Detail
  • Alfa Aesar

  • (L11510)  Bis(2-bromoethyl) ether, 96%   

  • 5414-19-7

  • 25g

  • 773.0CNY

  • Detail

5414-19-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,2'-Dibromodiethyl ether

1.2 Other means of identification

Product number -
Other names 2,2'-Dibromodiethyl Ether

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5414-19-7 SDS

5414-19-7Synthetic route

1,4-oxathiane-4,4-dioxide

1,4-oxathiane-4,4-dioxide

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

Conditions
ConditionsYield
With hydrogen bromide at 20℃; for 12h; Temperature;82.1%
diethylene glycol
111-46-6

diethylene glycol

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

Conditions
ConditionsYield
With phosphorus tribromide at 0 - 60℃; for 13h;80%
With phosphorus tribromide at 50 - 60℃; for 12h;80%
With phosphorus tribromide for 9.5h;33%
ethyl (2S)-2-[(diisopropylsilyl)oxy]propanoate
799296-23-4

ethyl (2S)-2-[(diisopropylsilyl)oxy]propanoate

2-bromoethanol
540-51-2

2-bromoethanol

A

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

B

ethyl (2S)-2-{[(2-bromoethoxy)(diisopropyl)silyl]oxy}propanoate
1202570-30-6

ethyl (2S)-2-{[(2-bromoethoxy)(diisopropyl)silyl]oxy}propanoate

Conditions
ConditionsYield
With bromopentacarbonylmanganese(I) In dichloromethane at 20℃; for 2h;A n/a
B 68%
3-oxa-1,5-dichloropentane
111-44-4

3-oxa-1,5-dichloropentane

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

Conditions
ConditionsYield
With potassium bromide In ethylene dibromide; N,N-dimethyl-formamide for 24h; Reflux;65%
diethylene glycol dimesylate
34604-52-9

diethylene glycol dimesylate

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

Conditions
ConditionsYield
With lithium bromide In acetone for 20h; Heating / reflux;50%
With lithium bromide In acetone for 20h; Heating;
oxirane
75-21-8

oxirane

ethene
74-85-1

ethene

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

Conditions
ConditionsYield
With bromine
With bromine In tetrachloromethane
1-methyl-1H-imidazole
616-47-7

1-methyl-1H-imidazole

1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

3,3′-(oxidi-2,1-ethanediyl)bis[1-methyl-imidazolium] dibromide

3,3′-(oxidi-2,1-ethanediyl)bis[1-methyl-imidazolium] dibromide

Conditions
ConditionsYield
In toluene Reflux; Inert atmosphere;100%
In toluene at 90℃; for 48h;99%
In acetonitrile for 48h; Reflux;95%
at 80℃; for 16h;
In 1,1,1-trichloroethane at 80℃; for 24h;
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

cis-(+/-)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one

cis-(+/-)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one

cis-2-[2-(2-bromoethoxy)ethyl]-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one

cis-2-[2-(2-bromoethoxy)ethyl]-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one

Conditions
ConditionsYield
Stage #1: cis-(+/-)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0℃;
Stage #2: 1,1'-oxybis(2-bromo-ethane) In N,N-dimethyl-formamide; mineral oil for 0.25h;
100%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

trans-4-(tert-butoxycarbonylamino)cyclohexylamine

trans-4-(tert-butoxycarbonylamino)cyclohexylamine

tert-butyl ((1,4-trans)-4-morpholinocyclohexyl)carbamate

tert-butyl ((1,4-trans)-4-morpholinocyclohexyl)carbamate

Conditions
ConditionsYield
With sodium carbonate In acetonitrile at 75℃; for 48h;100%
With triethylamine In N,N-dimethyl-formamide at 70℃; for 16h;
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

(3S)-4-[2-chloro-6-(methanesulfonylmethyl)pyrimidin-4-yl]-3-ethylmorpholine

(3S)-4-[2-chloro-6-(methanesulfonylmethyl)pyrimidin-4-yl]-3-ethylmorpholine

(3S)-4-[2-chloro-6-(4-methanesulfonyloxan-4-yl)pyrimidin-4-yl]-3-ethylmorpholine

(3S)-4-[2-chloro-6-(4-methanesulfonyloxan-4-yl)pyrimidin-4-yl]-3-ethylmorpholine

Conditions
ConditionsYield
With tetrabutylammomium bromide; sodium hydroxide In toluene at 90℃; for 2.25h; Sealed tube;100%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

borane-THF
14044-65-6

borane-THF

methylphenylphosphine
6372-48-1

methylphenylphosphine

2,2'-oxybis(ethane-2,1-diyl)bis(methylphenylphosphine-borane)
1147564-62-2, 1147564-78-0

2,2'-oxybis(ethane-2,1-diyl)bis(methylphenylphosphine-borane)

Conditions
ConditionsYield
With NaOCH(CH3)2CH2CH2; [RuH(1,2-bis(dimethylphosphino)ethane)((R)-DIFLUORPHOS)][tetraphenylborate] In tetrahydrofuran (N2); addn. of phosphine deriv. and benzyl chloride to THF soln. of sodium alcoholate deriv. and ruthenium compd., stirring at room temp. for 90min, addn. of THF soln. of borane deriv., stirring at room temp. for 30 min; addn. of water, extn. (ethyl acetate), washing with brine, drying over Na2SO4, filtration, concg., chromy. (silica gel, 75:25 hexanes/ethyl acetate), NMR and MS;99%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

trimethylamine
75-50-3

trimethylamine

(5-bromo-3-oxapentyl)trimethylammonium bromide

(5-bromo-3-oxapentyl)trimethylammonium bromide

Conditions
ConditionsYield
In tetrahydrofuran for 24h; Ambient temperature;98%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

diethyl malonate
105-53-3

diethyl malonate

(1-ethoxy-ethyl)-malonic acid diethyl ester
91368-89-7

(1-ethoxy-ethyl)-malonic acid diethyl ester

Conditions
ConditionsYield
With sodium In ethanol; hexane98%
With sodium In ethanol; hexane98%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

2-[3,5-bis(1-ethoxyethoxy)phenyl]acetonitrile

2-[3,5-bis(1-ethoxyethoxy)phenyl]acetonitrile

4-[3,5-bis(1-ethoxyethoxy)phenyl]tetrahydro-2H-pyran-4-carbonitrile

4-[3,5-bis(1-ethoxyethoxy)phenyl]tetrahydro-2H-pyran-4-carbonitrile

Conditions
ConditionsYield
Stage #1: 2-[3,5-bis(1-ethoxyethoxy)phenyl]acetonitrile With potassium hexamethylsilazane In tetrahydrofuran at -16℃; for 0.0833333h; Inert atmosphere;
Stage #2: 1,1'-oxybis(2-bromo-ethane) In tetrahydrofuran at -16℃; for 1h; Inert atmosphere;
98%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

1-(5-O-acetyl-2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)-thymine
77421-68-2

1-(5-O-acetyl-2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)-thymine

5'-O-acetyl-3-N-[2-(2-bromoethoxy)ethyl]-2',3'-didehydro-2',3'-dideoxythymidine
514213-69-5

5'-O-acetyl-3-N-[2-(2-bromoethoxy)ethyl]-2',3'-didehydro-2',3'-dideoxythymidine

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 80℃; for 1.5h;97%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

1,5-diazido-3-oxapentane
24345-74-2

1,5-diazido-3-oxapentane

Conditions
ConditionsYield
With sodium azide In N,N-dimethyl-formamide at 60℃; for 10h;97%
With sodium azide In N,N-dimethyl-formamide at 60℃; Inert atmosphere;95%
With sodium azide In N,N-dimethyl-formamide at 55℃; for 3h;
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

2-(((1R,3R)-3-(benzyloxy)cyclohexyl)oxy)-5-bromopyridin-3-amine

2-(((1R,3R)-3-(benzyloxy)cyclohexyl)oxy)-5-bromopyridin-3-amine

4-(2-(((1R,3R)-3-(benzyloxy)cyclohexyl)oxy)-5-bromopyridin-3-yl)morpholine

4-(2-(((1R,3R)-3-(benzyloxy)cyclohexyl)oxy)-5-bromopyridin-3-yl)morpholine

Conditions
ConditionsYield
Stage #1: 2-(((1R,3R)-3-(benzyloxy)cyclohexyl)oxy)-5-bromopyridin-3-amine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 25℃; for 0.5h;
Stage #2: 1,1'-oxybis(2-bromo-ethane) In N,N-dimethyl-formamide; mineral oil at 80℃; for 11.5h;
97%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

methyl salicylate
119-36-8

methyl salicylate

1,7-bis(2-(methoxycarbonyl)phenyl)-1,4,7-trioxaheptane
161724-78-3

1,7-bis(2-(methoxycarbonyl)phenyl)-1,4,7-trioxaheptane

Conditions
ConditionsYield
With potassium carbonate In acetone for 168h; Heating;96%
With potassium carbonate In acetone for 168h; Heating;90%
With potassium carbonate In acetone for 168h; Reflux;55%
With potassium carbonate In acetone Heating;
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

3-(2-imidazolin-1-yl)propyltriethoxysilane
63365-92-4

3-(2-imidazolin-1-yl)propyltriethoxysilane

3-[3-(triethoxysilyl)propyl]-1-[2-(2-{1-[3-(triethoxysilyl)propyl]-1H-imidazol-3-ium-3-yl}ethoxy)ethyl]-1H-imidazol-3-ium dibromide

3-[3-(triethoxysilyl)propyl]-1-[2-(2-{1-[3-(triethoxysilyl)propyl]-1H-imidazol-3-ium-3-yl}ethoxy)ethyl]-1H-imidazol-3-ium dibromide

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 120℃; for 4h;96%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

4-chloro-7-fluoro-7-deazapurine
582313-57-3

4-chloro-7-fluoro-7-deazapurine

7-(2-[2-bromoethoxy]ethyl)-4-chloro-5-fluoro-7H-pyrrolo-[2,3-d]pyrimidine

7-(2-[2-bromoethoxy]ethyl)-4-chloro-5-fluoro-7H-pyrrolo-[2,3-d]pyrimidine

Conditions
ConditionsYield
Stage #1: 4-chloro-7-fluoro-7-deazapurine With sodium hydride In mineral oil at 0 - 22℃; for 0.166667h;
Stage #2: 1,1'-oxybis(2-bromo-ethane) In N,N-dimethyl-formamide; mineral oil at 60℃; for 2h;
96%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

6-hydroxy-2-chloroquinoline
577967-89-6

6-hydroxy-2-chloroquinoline

C22H18Cl2N2O3

C22H18Cl2N2O3

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 70℃; for 4h;95.8%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

ethyl (6-chloro-pyridin-3-yl)acetate
197376-47-9

ethyl (6-chloro-pyridin-3-yl)acetate

ethyl 4-(6-chloropyridin-3-yl)tetrahydro-2H-pyran-4-carboxylate

ethyl 4-(6-chloropyridin-3-yl)tetrahydro-2H-pyran-4-carboxylate

Conditions
ConditionsYield
With lithium hexamethyldisilazane In tetrahydrofuran at -78 - 20℃; Inert atmosphere;95%
Stage #1: ethyl (6-chloro-pyridin-3-yl)acetate With sodium hydride In N,N-dimethyl-formamide; mineral oil for 0.666667h; Cooling with ice;
Stage #2: 1,1'-oxybis(2-bromo-ethane) In N,N-dimethyl-formamide; mineral oil at 0℃; for 3h;
0.82 g
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

2-(2-(difluoro(trifluoromethoxy)methoxy)-1,1,2,2-tetrafluoroethoxy)-N-(3-(dimethylamino)propyl)-2,3,3,3-tetrafluoropropanamide

2-(2-(difluoro(trifluoromethoxy)methoxy)-1,1,2,2-tetrafluoroethoxy)-N-(3-(dimethylamino)propyl)-2,3,3,3-tetrafluoropropanamide

N,N'-(oxybis(ethane-2,1-diyl))bis(1,1,1,3,3,5,5,6,6,8-decafluoro-N,N-dimethyl-9-oxo-8-(trifluoromethyl)-2,4,7-trioxa-10-azatridecan-13-aminium) bromide

N,N'-(oxybis(ethane-2,1-diyl))bis(1,1,1,3,3,5,5,6,6,8-decafluoro-N,N-dimethyl-9-oxo-8-(trifluoromethyl)-2,4,7-trioxa-10-azatridecan-13-aminium) bromide

Conditions
ConditionsYield
In acetonitrile at 80℃; for 12h; Schlenk technique;95%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

N,N',N'',N'''-tetratosyl-1,10-diamino-4,7-diazadecane
74676-47-4

N,N',N'',N'''-tetratosyl-1,10-diamino-4,7-diazadecane

4,8,11,15-tetrakis(p-tolylsulphonyl)-1-oxa-4,8,11,15-tetraazacycloheptadecane
120808-61-9

4,8,11,15-tetrakis(p-tolylsulphonyl)-1-oxa-4,8,11,15-tetraazacycloheptadecane

Conditions
ConditionsYield
With sodium hydroxide; tetra-(n-butyl)ammonium iodide In toluene for 10h; Heating;94%
With sodium hydroxide; tetra-(n-butyl)ammonium iodide In water; toluene for 9h; Heating;94%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

(1S,2S,3R,5S)-3-amino-2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol
69363-09-3

(1S,2S,3R,5S)-3-amino-2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol

(1S,2S,3R,5S)-2,6,6-trimethyl-3-morpholinobicyclo[3.1.1]heptan-2-ol

(1S,2S,3R,5S)-2,6,6-trimethyl-3-morpholinobicyclo[3.1.1]heptan-2-ol

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 18h; Reflux;94%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

2-bromo-5-((4-(3-hydroxyphenyl)pyrimidin-2-yl)amino)phenol

2-bromo-5-((4-(3-hydroxyphenyl)pyrimidin-2-yl)amino)phenol

C20H18BrN3O3

C20H18BrN3O3

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 75℃; for 20h;94%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

diethylene glycol dinitrate
693-21-0

diethylene glycol dinitrate

Conditions
ConditionsYield
With silver nitrate In acetonitrile at 70℃; for 16h; Darkness;93.4%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

(1S,2R)-(+)-norphedrine
37577-28-9

(1S,2R)-(+)-norphedrine

(1S,2R)-2-(morpholin-4-yl)-1-phenylpropanol

(1S,2R)-2-(morpholin-4-yl)-1-phenylpropanol

Conditions
ConditionsYield
With sodium hydrogencarbonate In toluene for 22.5h; Heating;93%
Stage #1: 1,1'-oxybis(2-bromo-ethane); (1S,2R)-(+)-norphedrine With sodium hydrogencarbonate In toluene at 115℃; for 22.5h;
Stage #2: With sodium hydroxide In water pH=13;
93%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

1-(6-chloropyridin-3-yl)cyclohexanamine

1-(6-chloropyridin-3-yl)cyclohexanamine

4-(1-(6-chloropyridin-3-yl)cyclohexyl)morpholine

4-(1-(6-chloropyridin-3-yl)cyclohexyl)morpholine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile at 120℃; Sealed tube;93%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

(3-bromophenyl)acetonitrile
31938-07-5

(3-bromophenyl)acetonitrile

4-(3-Bromo-phenyl)-tetrahydro-pyran-4-carbonitrile
245439-36-5

4-(3-Bromo-phenyl)-tetrahydro-pyran-4-carbonitrile

Conditions
ConditionsYield
Stage #1: (3-bromophenyl)acetonitrile With sodium hydride In N,N-dimethyl-formamide at 0℃; for 0.25h;
Stage #2: 1,1'-oxybis(2-bromo-ethane) In N,N-dimethyl-formamide at 0 - 20℃; for 4h;
93%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on
485-72-3

7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on

7-(2-(2-bromoethoxy)-ethoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one

7-(2-(2-bromoethoxy)-ethoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one

Conditions
ConditionsYield
With potassium carbonate In acetone at 60℃; for 10h;93%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

3'-azido-2',3'-deoxythymidine
30516-87-1

3'-azido-2',3'-deoxythymidine

3'-azido-3-N-(5-bromoethyl ether)-3'-deoxythymidine

3'-azido-3-N-(5-bromoethyl ether)-3'-deoxythymidine

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide; acetone for 24h; Alkylation; Heating;92%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

4,4'-bis(hydroxy)-3,3'-oxybis(ethyleneoxy)dibenzaldehyde
486395-57-7

4,4'-bis(hydroxy)-3,3'-oxybis(ethyleneoxy)dibenzaldehyde

6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2,14-dicarbaldehyde
90265-03-5

6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2,14-dicarbaldehyde

Conditions
ConditionsYield
With potassium carbonate; potassium iodide In N,N-dimethyl-formamide at 80℃; for 43.5h; Williamson macrocyclization;92%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

p-aminophenylacetonitrile
3544-25-0

p-aminophenylacetonitrile

2-[4-(morpholin-4-yl)phenyl]acetonitrile
1000512-72-0

2-[4-(morpholin-4-yl)phenyl]acetonitrile

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In toluene for 20h; Reflux;92%
With N-ethyl-N,N-diisopropylamine In toluene for 20h; Reflux;92%
With N-ethyl-N,N-diisopropylamine In toluene for 20h; Reflux;
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

(R)-Phenylglycinol
56613-80-0

(R)-Phenylglycinol

(R)-2-morpholino-2-phenylethan-1-ol

(R)-2-morpholino-2-phenylethan-1-ol

Conditions
ConditionsYield
With potassium carbonate In ethanol at 80℃; for 24h;92%
1,1'-oxybis(2-bromo-ethane)
5414-19-7

1,1'-oxybis(2-bromo-ethane)

tert-butyl {[5-(4-butoxyphenyl)thien-2-yl]sulfonyl}acetate
701270-40-8

tert-butyl {[5-(4-butoxyphenyl)thien-2-yl]sulfonyl}acetate

tert-butyl 4-{[5-(4-butoxyphenyl)thien-2-yl]sulfonyl}tetrahydro-2H-pyran-4-carboxylate
701270-41-9

tert-butyl 4-{[5-(4-butoxyphenyl)thien-2-yl]sulfonyl}tetrahydro-2H-pyran-4-carboxylate

Conditions
ConditionsYield
With 18-crown-6 ether; potassium carbonate In DMF (N,N-dimethyl-formamide) at 65℃; for 15h;91%

5414-19-7Relevant academic research and scientific papers

Solubility of 3,3′-(Oxidi-2,1-ethanediyl)bis[1-methyl-imidazolium] Dihexafluorophosphate in Water, Methanol, Ethanol, Acetone, and Acetonitrile and Binary Mixtures (Water + DMF) from (283.00 to 323.00) K

Guo, Jia-Rong,Xu, Bin,Wang, Yan,Zhuang, Ling-Hua,Wang, Guo-Wei

, p. 1091 - 1097 (2015)

3,3′-(Oxidi-2,1-ethanediyl)bis[1-methyl-imidazolium] dihexafluorophosphate ([C4O(mim)2][PF6]2) was synthesized and confirmed with 1H NMR and FT-IR. The thermal stability of [C4O(mim)2][PF6]2 was studied with differential scanning calorimetry and thermogravimetric analyses. Using the dynamic method, the solubility of [C4O(mim)2][PF6]2 in five different pure solvents (water, methanol, ethanol, acetone, and acetonitrile) and binary mixtures (water + DMF) was measured at the temperature range from (283.00 to 323.00 K) at atmospheric pressure. The solubility of [C4O(mim)2][PF6]2 in those selected solvents increased with increasing temperature and DMF contents, but the rate of solubility is different. The experimental data were correlated with the modified Apelblat equation. Also, the solubility of [C4O(mim)2][PF6]2 and [C6O2(mim)2][PF6]2 was been compared in the same solvent. (Graphical Presented).

Synthesis of new heterocyclic dehydroabietylamine derivatives and their biological activity

Kovaleva, Kseniya S.,Yarovaya, Olga I.,Shernyukov, Andrey V.,Zarubaev, Vladimir V.,Shtro, Anna A.,Orshanskaya, Yana R.,Salakhutdinov, Nariman F.

, p. 364 - 370 (2017)

(figure presented) New derivatives of dehydroabietylamine were obtained by transformation of primary amino group to pyrrolidine, piperidine, azepane, morpholine, isoindoline, and pyrrole heterocycles. The obtained compounds were tested for antiviral activity against influenza A/California/07/09 (H1N1)pdm09 strain, as well as the activity against some types of bacteria and fungi.

COMPOUND, DECORATIVE MATERIAL, DECORATED ARTICLE, AND INK COMPOSITION

-

Paragraph 0105; 0114-0116; 0130-0132, (2020/03/27)

To provide a compound exhibiting golden glossiness and providing a film having flexibility.SOLUTION: There is provided a compound represented by the formula (1). Rand Rare each independently a substituted or unsubstituted C1 to 12 alkyl group, -(CH)-COO-R, -(CH)-O-R, -(CH)-CONH-R, -(CH)-CONH-(CH)-OH or the like; Rto Rare each independently a C1 to 6 alkyl group; nis an integer of 2 to 10; and mto mare integer of 1 to 6.SELECTED DRAWING: None

Compound, conjugate, kit, and application of kit in detection of estradiol

-

Paragraph 0096; 0103; 0104, (2018/03/26)

The invention discloses a compound, a conjugate, a kit for detecting estradiol, and an application of the kit for detecting the estradiol in detection of the estradiol. The compound has a structure shown as a formula (1), wherein the L represents a connecting arm, the R, R, R and R are respectively independently a hydrogen group, a hydroxyl group, an alkyl of C, an alkoxy of C, an alkenyl of C or an alkynyl of C. The compound disclosed by the invention can be used for accurately detecting estradiol.

Double (2-haloethyl) ether synthesis method

-

Paragraph 0032-0033, (2017/02/24)

The invention relates to the synthesis of fine chemical intermediates, in particular to a synthesis method of di(2-halogenated ethyl) ether. According to the synthesis method, 1,4-thioxane-1,1-dioxo and a hydrogen halide water solution react with each other to obtain the target product, namely di(2-halogenated ethyl) ether. The synthesis method is simple and convenient in technical route, good in selectivity, high in yield, less in pollution and simple in post-processing, conforms to the tendency of the green chemical industry nowadays, and has great industrial value.

A delocalizable cationic headgroup together with an oligo-oxyethylene spacer in gemini cationic lipids improves their biological activity as vectors of plasmid DNA

Kumar, Krishan,Barrn-Berdn, Ana L.,Datta, Sougata,Muoz-beda, Mnica,Aicart-Ramos, Clara,Kondaiah, Paturu,Junquera, Elena,Bhattacharya, Santanu,Aicart, Emilio

, p. 1495 - 1506 (2015/03/04)

Lipoplex nano-aggregates constituted of plasmid DNA (pDNA) pEGFP-C3 and mixed cationic liposomes, consisting of several percentages of a gemini cationic lipid (GCL) of the 1,2-bis(hexadecyl imidazolium) oxyethylene series, referred to as (C16Im)2(C2O)n, with oxyethylene spacers (n = 1, 2 or 3) between the imidazolium cationic groups and the DOPE zwitterionic helper lipid, have been characterized by various biophysical and biological approaches carried out at several GCL compositions (α), and either the mass or the effective charge ratio of the lipoplex. The electrochemical study by ζ-potential confirms that the three GCLs yield a 10% lower effective charge than the nominal one, while compacted pDNA yields only a 25% effective negative charge. The SAXS study reveals, irrespective of the spacer length (n) and effective charge ratio (ρeff), the presence of two lamellar structures, i.e., one (Lα,main) in the whole GCL composition and another (Lα,DOPE,rich) with higher periodicity values that coexists with the previous one at low GCL composition (α = 0.2). The cryo-TEM analysis shows two types of multilamellar structures consisting of cationic lipidic bilayers with pDNA sandwiched between them: a cluster-type (C-type) at low α = 0.2 and a fingerprint-type (FP-type) at α ≥ 0.5, both with similar interlamellar spacing (d) in agreement with the Lα,main structure determined by SAXS. Transfection efficacies (TEs) of each lipid mixture were determined in four different cell lines (HEK293T, HeLa, Caco-2 and A549) at several α and ρeff values in the absence and presence of serum (FBS). The optimized formulations (α = 0.2 and ρeff = 2.0) substantially transfect cells much better than a commercial transfection reagent, Lipofectamine 2000 and previously studied efficient lipoplexes containing other cationic head groups or spacers both in the absence and presence of serum. The activity of optimized formulations may be attributed to the combination of several factors, such as: (a) the fusogenic character of DOPE which results in higher fluidity of the lipoplexes at α = 0.2, (b) the coexistence of two lamellar structures at α = 0.2 that synergizes the TE of these lipid vectors, and mainly (c) the higher biocompatibility of the GCLs reported in this work due to the presence of two imidazolium cationic groups together with an oligo-oxyethylene spacer. The length of the spacer in the GCL seems to have less impact, although (C16Im)2(C2O)n/DOPE-pDNA lipoplexes with n = 1 and 3 show higher gene transfection than n = 2. All the optimum formulations reported herein are all highly efficient with negligible levels of toxicity, and thus, may be considered as very promising gene vectors for in vivo applications. This journal is

Cationic gemini lipids containing polyoxyethylene spacers as improved transfecting agents of plasmid DNA in cancer cells

Barran-Berdon, Ana L.,Misra, Santosh K.,Datta, Sougata,Munoz-Ubeda, Monica,Kondaiah, Paturu,Junquera, Elena,Bhattacharya, Santanu,Aicart, Emilio

supporting information, p. 4640 - 4652 (2014/07/21)

Lipoplex nano-aggregates have been analyzed through biophysical characterization (electrostatics, structure, size and morphology), and biological studies (transfection efficiency and cell viability) in five cancer cell lines. Lipoplexes were prepared from pEGFP-C3 plasmid DNA (pDNA) and mixed liposomes, constituted by a zwitterionic lipid (DOPE) and a gemini cationic lipid (GCL) synthesized in this work, [bis(hexadecyl dimethyl ammonium) oxyethylene], referred to as (C16Am)2(C2O) n, (where n is the oxyethylene spacer length, n = 1, 2 or 3, between the ammonium heads). Cryo-TEM micrographs show nano-aggregates with two multilamellar structures, a cluster-type (at low-to-medium GCL composition) and a fingerprint-type that coexists with the cluster-type at medium GCL composition and appears alone at high GCL composition. SAXS diffractograms show that these lipoplexes present three lamellar structures, two of them coexisting at low and high GCL composition. The optimized transfection efficiency (TE) of pDNA was higher for lipoplexes containing GCLs with a longer (n = 3) or shorter (n = 1) polyoxyethylene spacer, at high GCL composition (α = 0.7) with low charge ratio (ρeff = 2). In the all cancer cell lines studied, the TE of the optimized formulations was much better than those of both lipofectamine 2000 and lipoplexes with GCLs of the bis(hexadecyl dimethyl ammonium) alkane series recently reported. Probably, (a) the coexistence of two lamellar structures at high GCL composition synergizes the TE of these lipid vectors, (b) the orientation of the polyoxyethylene region in (C16Am) 2(C2O)3/DOPE may occur in such a way that the spacing between two cationic heads becomes smaller than that in (C 16Am)2(C2O)2/DOPE which is poor in terms of TE, and (c) the synergistic interactions between serum proteins and (C16Am)2(C2O)n/DOPE-pDNA lipoplexes containing a polyoxyethylene spacer improve TE, especially at high GCL content. Lipoplexes studied here show very low levels of toxicity, which confirm them as improved vectors of pDNA in gene therapy.

Determination of micellar aggregation numbers of gemini surfactant in aqueous solution by steady-state fluorescence quenching method

Jie, Ni Ren,Ling, Wang Ya,Yu, Huang,Cheng, Yao

experimental part, p. 5011 - 5014 (2012/10/08)

A new kind of Gemini surfactant synthesized from the intermediate 1-bromo-2-(2-bromoethoxy)ethane and dodecyl dimethyl amine by using isopropanol as solvent. The critical micellar concentration (CMC) value of Gemini 12-Y-12 determined by Steady-state fluorescence quenching (SSFQ) method is basically in agreement with the value by surface tension method. The micellar aggregation numbers (Nagg) of this surfantant are essentially constant when the concentrations of the quencher were selected in 2.0 × 10-4-5.0 × 10-4 mol L-1. The Nagg of the Gemini surfactant increases linearly with the increase of surfactant concentration in the range of 4-9 times of critical micellar concentration and critical micellar aggregation numbers obtained by extrapolation method is 13.2.

Spectroscopic studies of the interaction between methyl orange and gemini surfactant

Jia,Gong,Ni,Su,Yao

scheme or table, p. 729 - 732 (2012/01/02)

The influence of two kinds of cationic surfactants on spectral properties of methyl orange in aqueous solutions has been investigated by means of UV-vis spectroscopy in various pH values and concentration range. For the Gemini14-methyl orange (MO) solutions, a hyperchromic shift was observed from 509-403 nm with the decrease of spectra absorption by increasing the pH values. Spectral behaviour of dye-surfactant solutions with varying concentrations of surfactants confirmed that electrostatic hydrophobic interactions between dye and surfactant played an important role. An H-type aggregation appeared in the concentration ratio 1:2 for Gemini14 and methyl orange, but in the CTAB solutions, the ratio was 1:1. The initial decrease of the absorbance resulted from dye-surfactant complex formation. It can be concluded that the amount of the cationic groups plays an important role in the complex formation.

A mild synthesis of unsymmetrical bisalkoxysilanes through catalyzed alcoholysis of hydridosilanes containing C-C multiple bonds and aryl halides

Scott, Colleen N.,Wilcox, Craig S.

experimental part, p. 253 - 256 (2010/04/06)

(Chemical Equation Presented) The synthesis of unsymmetrical bisalkoxysilanes containing unsaturated C-C bonds and alkyl and aryl bromides has been developed. This method is a modification of our previously reported two-step procedure that utilizes readily available catalysts (rhodium acetate dimer and manganese pentacarbonyl bromide) under mild neutral aprotic conditions. Good to moderate yields of the products were obtained in a short period. In this two-step synthesis, unsymmetrical bisalkoxysilanes with groups that can be further functionalized can be prepared effectively without the need to isolate the intermediates. 2009 American Chemical Society.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 5414-19-7